DexCom, Inc. (DXCM)
DexCom makes clever wearable sensors that help people with diabetes track their blood sugar levels in real-time without needing constant finger pricks.
Is DexCom, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: High profit margins on their core products. Worth weighing: No dividend payments for shareholders.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Share price divided by the earnings actually reported over the four most recent quarters. The range is the same calculation at each of this company's last few results, so roughly the past year.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does DexCom, Inc. do?
DexCom is a leader in continuous glucose monitoring, selling small, disposable sensors that send blood sugar data straight to a smartphone. Its earnings come from selling these sensors and the accompanying transmitters, which need to be replaced regularly. How they fend off rival medical device makers and keep expanding their user base worldwide is what to follow.
On our factor screen it looks strongest on momentum and quality, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 13% over the year
- ✓Very profitable - turns about 20% of sales into profit
- !High P/E of 35 - big growth is already priced in
- ✓Strong return on shareholder money (ROE 38%)
- Quality screens high
- Momentum screens high
- Value screens low
- Income screens low
Does DexCom, Inc. pay a dividend?
No - DexCom, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does DexCom, Inc. have more cash or more debt?
It holds about $1.95B in cash against about $1.40B of debt - so it has net cash of about $548.60M. More cash than debt is a cushion: it does not need to borrow just to cover what it owes.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do DexCom, Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has DexCom, Inc. actually fallen?
Over the last 2 years of daily prices, DexCom, Inc. fell as much as −40% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does DexCom, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Where does each £100 of DexCom, Inc.'s sales go?
A rough split of the latest full-year figures: of every £100 of sales, about £38 covers making the product or service, £42 goes on running costs, tax and interest, and about £20 is left as profit. Margins vary a lot by industry, and one-off items can distort a single year.
When does DexCom, Inc. report earnings, and how did recent quarters go?
DexCom, Inc. is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $0.61 | $0.70 | Beat +15% |
| 2026-04-30 | $0.47 | $0.56 | Beat +19% |
| 2026-02-12 | $0.65 | $0.68 | Beat +4% |
| 2025-10-30 | $0.57 | $0.61 | Beat +8% |
| 2025-07-30 | $0.44 | $0.48 | Beat +8% |
| 2025-05-01 | $0.33 | $0.32 | Missed -3% |
Across the last 6 quarters here, DexCom, Inc. came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for DexCom, Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Widespread adoption of sensors for non-insulin users
Technological obsolescence or major product recalls
What are the pros and cons of DexCom, Inc.?
A balance check, not a score or verdict.
- High profit margins on their core products
- Strong growth in earnings compared to the previous year
- Essential technology with a loyal customer base
- No dividend payments for shareholders
- High price-to-book: The share price versus the company's net assets per share (its book value). Under 1 can look cheap, though it varies a lot by industry. ratio suggests the shares are priced at a premium to their physical assets
- The share price has been volatile over the last year
- Intense competition from other medical device companies
- Reliance on insurance companies to cover the cost of sensors
- Potential for regulatory hurdles in new international markets
The write-up's own warning lights — if these start happening, the case above changes.
- A significant drop in the company's profit margins
- Loss of market share to a cheaper or more effective competitor
Common questions about DexCom, Inc.
Does DexCom, Inc. pay a dividend?
No - DexCom, Inc. does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does DexCom, Inc. report earnings next?
DexCom, Inc. is next scheduled to report results on about 2026-10-29. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
Revvity, Inc.
Cencora, Inc.
Amgen Inc.
Merck & Co., Inc.
Biogen Inc.
Bio-Techne Corporation
STERIS plc
Centene CorporationBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.